Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.53 |
| ▸ | PDE4A | P27815 | 8/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.48 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770686 | 0.89 | DCTPP1 (0.51) | ADORA3DCTPP1NPC1RAB9A | |
| SCHEMBL4765718 | 0.87 | PDE4D (0.46) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4767937 | 0.84 | PDE4A (0.46) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5741824 | 0.83 | PDE1A (0.47) | ADORA3DCTPP1PROKR1NPC1RAB9A | |
| SCHEMBL4769603 | 0.82 | DCTPP1 (0.46) | ADORA3DCTPP1NPC1RAB9A | |
| SCHEMBL4762278 | 0.82 | DCTPP1 (0.49) | DCTPP1NPC1RAB9A | |
| SCHEMBL4762551 | 0.80 | PDE5A (0.40) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4762307 | 0.80 | DCTPP1 (0.44) | ADORA3DCTPP1NPC1RAB9A | |
| SCHEMBL4790609 | 0.78 | MAPT (0.44) | DCTPP1 | |
| SCHEMBL4767817 | 0.77 | PARG (0.38) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | PDE5A 736/4885PDE4A 182/4885PDE4B 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.